期刊
INVESTIGATIONAL NEW DRUGS
卷 27, 期 6, 页码 565-570出版社
SPRINGER
DOI: 10.1007/s10637-009-9220-1
关键词
Enzastaurin; Metastatic breast cancer; Phase II
Purpose: Enzastaurin is a potent, serine-threonine kinase inhibitor which selectively targets PKC beta and PI3K/AKT signaling pathways to reduce cell proliferation, induce apoptosis, and inhibit angiogenesis. As PKC beta and PI3K/AKT signaling are both involved in breast cancer pathogenesis, this phase II study evaluated the efficacy and toxicity of enzastaurin in previously treated patients with metastatic breast cancer (MBC). Patients and Methods: Eligible patients had histologically confirmed MBC with measurable disease, and must have received prior anthracycline and taxane chemotherapy, but not more than two prior regimens for MBC. Human epidermal growth factor 2 (HER2)-positive patients must have progressed on prior trastuzumab therapy. Enzastaurin, 1,125-mg loading dose on day 1 followed by 500 mg daily, was administered orally in 28-day cycles. Response was assessed every 2 cycles according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. Results: Twenty-one patients enrolled between November 2006 and September 2007. Fourteen (66.7%) patients completed at least two cycles of therapy. No patients developed Grade 3/4 hematologic toxicity. Grade 3 nonhematologic toxicity was rare (< 5%) and most commonly attributed to MBC progression. There were no objective responses and no patients with stable disease for a parts per thousand yen6 months. Median progression-free survival was 1.68 months (95%CI: 1.02, 1.74). Conclusions: Enzastaurin monotherapy was well tolerated, but demonstrated no activity in patients with heavily pretreated MBC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据